Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 16,388 shares, an increase of 177.1% from the May 14th total of 5,914 shares. Based on an average daily trading volume, of 8,366 shares, the short-interest ratio is currently 2.0 days. Approximately 0.8% of the shares of the stock are short sold.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Stock Up 6.7%

Shares of XBIO stock traded up $0.20 during trading on Friday, hitting $3.20. The company had a trading volume of 46,698 shares, compared to its average volume of 13,293. The stock’s 50-day moving average is $3.13 and its two-hundred day moving average is $2.67. The stock has a market capitalization of $7.33 million, a price-to-earnings ratio of -2.67 and a beta of 2.19. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.81 million during the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.